Mitolactol - Eleison Pharmaceuticals
Alternative Names: Bromoalcohol; DBD; Dibromdicil; Dibromodulcitol; Elobromol; Metholactole; Mitolactol-Chinoin; NSC 104800; WR 138743Latest Information Update: 06 Jan 2022
At a glance
- Originator Chinoin
- Class Antineoplastics; Peptides; Small molecules
- Mechanism of Action Alkylating agents; DNA inhibitors; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Cancer
- Discontinued Brain cancer; Cervical cancer
Most Recent Events
- 28 May 2021 Eleison Pharmaceuticals plans a pivotal phase III trial in Brain cancer in 2022 or 2023
- 10 Dec 2020 Eleison has patent protection for Composition of matter in the US
- 04 Dec 2019 Eleison Pharmaceuticals enters into a licensing agreement with Targent for the development and commercialisation of mitaloacol (Dibromodulcitol)